Fennec Pharmaceuticals Inc. (FRA:RV41)
Germany
· Delayed Price · Currency is EUR 6.50
-0.15 (-2.26%)
At close: Dec 5, 2025
Fennec Pharmaceuticals Company Description
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc.
| Country | Canada |
| Founded | 1996 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 32 |
| CEO | Jeffrey Hackman |
Contact Details
Address: 68 TW Alexander Drive Research Triangle Park, British Columbia 27709 United States | |
| Phone | 919 636 4530 |
| Website | fennecpharma.com |
Stock Details
| Ticker Symbol | RV41 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey Hackman | Chief Executive Officer |
| Robert Andrade | Chief Financial Officer |